Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines

(2021) Jee Hye Kang et al.   TRENDS IN IMMUNOLOGY

Hematological immune related adverse events after treatment with immune checkpoint inhibitors

(2021) Rafaela Kramer et al.   EUROPEAN JOURNAL OF CANCER

Thyroid immune-related adverse events following immune checkpoint inhibitor treatment

(2021) Christopher A Muir et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis

(2021) Paaladinesh Thavendiranathan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Endocrine toxicities of immune checkpoint inhibitors

(2021) Jordan J. Wright et al.   Nature Reviews Endocrinology

Immune checkpoint inhibitors-induced nephropathy: a French national survey

(2021) Alexandre O. Gérard et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2021) Theresa A McDonagh et al.   EUROPEAN HEART JOURNAL

Immune-related cholangitis induced by immune checkpoint inhibitors

(2021) Borui Pi et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study

(2021) Marije S. Koks et al.   PLoS One

Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement

(2021) Joerg Herrmann et al.   EUROPEAN HEART JOURNAL

Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer

(2021) Jake S. Jacob et al.   Journal of the National Comprehensive Cancer Network

68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis

(2021) Sarah Boughdad et al.   Journal for ImmunoTherapy of Cancer

How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors

(2021) B. Jordan et al.   ESMO Open

Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: a Systematic Review

(2020) Michael Collins et al.   Clinical Gastroenterology and Hepatology

Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis

(2020) Magid Awadalla et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study

(2020) Frank B. Cortazar et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Tocilizumab for refractory severe immune checkpoint inhibitor–associated myocarditis

(2020) J. Doms et al.   ANNALS OF ONCOLOGY

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

(2020) Marie Kostine et al.   ANNALS OF THE RHEUMATIC DISEASES

CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events

(2020) Amaris N. Geisler et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Immune Checkpoint Inhibitor‐Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis

(2020) Virginie Grouthier et al.   ONCOLOGIST

Chronic immune checkpoint inhibitor pneumonitis

(2020) Jarushka Naidoo et al.   Journal for ImmunoTherapy of Cancer

Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes

(2020) Alejandro Meraz-Muñoz et al.   Journal for ImmunoTherapy of Cancer

Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy

(2020) John Haanen et al.   Journal for ImmunoTherapy of Cancer

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events

(2020) Sandra M. Herrmann et al.   Kidney International Reports

Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis

(2020) B.C. Özdemir et al.   ANNALS OF ONCOLOGY

Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque

(2020) Zsofia D. Drobni et al.   CIRCULATION

Immune Checkpoint Inhibitor-Associated Glomerular Disease: A Systematic Review and Descriptive Analysis

(2020) Abhijat Kitchlu et al.   Kidney International Reports

Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia

(2020) James W. Smithy et al.   JOURNAL OF IMMUNOTHERAPY

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities

(2019) Filipe Martins et al.   LANCET ONCOLOGY

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury

(2019) Hamzah Abu-Sbeih et al.   Journal for ImmunoTherapy of Cancer

A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors

(2019) Jeroen de Filette et al.   HORMONE AND METABOLIC RESEARCH

Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy

(2019) Karen Bitton et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors

(2019) Rebecca Karp Leaf et al.   AMERICAN JOURNAL OF HEMATOLOGY

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors

(2019) Tenglong Tang et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy

(2019) Daniel Johnson et al.   Cancer Immunology Research

Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review

(2019) Jeroen M.k. de Filette et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Treatment Outcomes of Immune-Related Cutaneous Adverse Events

(2019) Gregory S. Phillips et al.   JOURNAL OF CLINICAL ONCOLOGY

Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy

(2019) Khashayar Esfahani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis

(2019) Joe-Elie Salem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis

(2019) Alexander Faje et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early infliximab in life-threatening immune-mediated pneumonitis

(2019) T Cooksley et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors

(2019) Harish Seethapathy et al.   Clinical Journal of the American Society of Nephrology

Eltrombopag treatment for severe refractory thrombocytopenia caused by pembrolizumab

(2019) Peng Song et al.   EUROPEAN JOURNAL OF CANCER

Budesonide treatment for microscopic colitis from immune checkpoint inhibitors

(2019) Michael S. Hughes et al.   Journal for ImmunoTherapy of Cancer

Management of pulmonary toxicity associated with immune checkpoint inhibitors

(2019) Myriam Delaunay et al.   European Respiratory Review

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

(2019) Hamzah Abu-Sbeih et al.   JOURNAL OF CLINICAL ONCOLOGY

Vasculitis associated with immune checkpoint inhibitors—a systematic review

(2018) Anisha Daxini et al.   CLINICAL RHEUMATOLOGY

Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis

(2018) Yinghong Wang et al.   INFLAMMATORY BOWEL DISEASES

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

(2018) Eleonora De Martin et al.   JOURNAL OF HEPATOLOGY

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

(2018) Syed S. Mahmood et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors

(2018) Ioannis Gkiozos et al.   Journal of Thoracic Oncology

Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury

(2018) Yoh Zen et al.   MODERN PATHOLOGY

Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade

(2018) Kerry Reynolds et al.   ONCOLOGIST

Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients

(2018) Michael T. Tetzlaff et al.   Journal for ImmunoTherapy of Cancer

Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis

(2018) Fausto Petrelli et al.   EUROPEAN JOURNAL OF CANCER

Pneumonitis in Non-Small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors

(2018) Karthik Suresh et al.   Journal of Thoracic Oncology

Immune checkpoint inhibitors and cardiovascular toxicity

(2018) Alexander R Lyon et al.   LANCET ONCOLOGY

Rheumatic immune-related adverse events from cancer immunotherapy

(2018) Leonard H. Calabrese et al.   Nature Reviews Rheumatology

Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer

(2018) Mehdi Touat et al.   NEUROLOGY

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis

(2018) Hamzah Abu-Sbeih et al.   Journal for ImmunoTherapy of Cancer

Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institutional, retrospective analysis with stratification of reactions by toxicity and implications for management

(2018) Emily Coleman et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

(2018) Nicolas Delanoy et al.   Lancet Haematology

A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab

(2018) Jaqueline Ghosn et al.   Journal for ImmunoTherapy of Cancer

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

(2017) Jarushka Naidoo et al.   JOURNAL OF CLINICAL ONCOLOGY

Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature

(2017) Laura C. Cappelli et al.   ARTHRITIS CARE & RESEARCH

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

(2017) Chipman RG Stroud et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Immune checkpoint inhibitors-related orchitis

(2016) F. Brunet-Possenti et al.   ANNALS OF ONCOLOGY

Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab

(2016) S. Cousin et al.   ANNALS OF ONCOLOGY

PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

(2016) M. Nishino et al.   CLINICAL CANCER RESEARCH

Ocular and orbital side-effects of checkpoint inhibitors

(2016) Joëlle Antoun et al.   CURRENT OPINION IN ONCOLOGY

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

(2016) V.R. Belum et al.   EUROPEAN JOURNAL OF CANCER

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

(2016) L. Marthey et al.   Journal of Crohns & Colitis

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

(2016) Camille Hua et al.   JAMA Dermatology

Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer

(2016) Mizuki Nishino et al.   JAMA Oncology

Ipilimumab-associated Hepatitis

(2015) Melanie Johncilla et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy

(2015) Mizuki Nishino et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement

(2014) Jacqueline Jonklaas et al.   THYROID

An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias

(2013) William D. Travis et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

A Severe Case of Ipilimumab-Induced Guillain-Barré Syndrome Revealed by an Occlusive Enteric Neuropathy

(2012) Caroline Gaudy-Marqueste et al.   JOURNAL OF IMMUNOTHERAPY

Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy

(2011) Katarzyna D. Chmiel et al.   JOURNAL OF CLINICAL ONCOLOGY

Inflammatory Enteric Neuropathy With Severe Constipation After Ipilimumab Treatment for Melanoma

(2009) Shailender Bhatia et al.   JOURNAL OF IMMUNOTHERAPY